ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2013
Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Prognostic value of the StAN score in elderly small cell lung cancer.Scientific reports · 2025Article
- Article
- Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Development of an algorithm to identify small cell lung cancer patients in claims databases.Frontiers in oncology · 2024Article
- Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients.Journal of geriatric cardiology : JGC · 2023Article
- Article
- Comparative study of survival among small cell lung cancer patients in the U.S. military health system and those in the surveillance, epidemiology, and end results (SEER) program.Annals of epidemiology · 2021Article
- Octogenarians may benefit from stage-specific small cell lung cancer treatment.Translational lung cancer research · 2021Article
- Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.Bosnian journal of basic medical sciences · 2021Article
- Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC.JTO clinical and research reports · 2021Article
- Antitumor effect of kurarinone and underlying mechanism in small cell lung carcinoma cells.OncoTargets and therapy · 2019Article
- Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages.Scientific reports · 2017Article
- Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.Cancer · 2016Article
- Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2016Article
- From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).PloS one · 2016Article
- The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionThis retrospective cohort study was designed to analyze factors associated with administration of chemotherapy and to examine the impact of chemotherapy on survival among elderly patients with small-cell lung cancer (SCLC) in the community.
methodsElderly patients aged 65 years and older with SCLC diagnosed between 1992 and 2001 were selected from the Surveillance, Epidemiology, and End Results-Medicare database. Logistic regression was used to evaluate which covariates influenced receipt of chemotherapy. Cox proportional hazards regression was used to examine the influence of clinical and demographic variables on survival. The independent effect of chemotherapy on survival was determined using propensity scores and quantile regression.
resultsIn the final cohort of 10,428 patients, 67.1% received chemotherapy, 39.1% received radiation, 3.4% received surgery, and 21.8% received no treatment. The most common chemotherapy regimens included etoposide combined with either cisplatin or carboplatin. Patients aged 85 years and older were significantly less likely to receive chemotherapy compared with patients aged 65 to 69 years (odds ratio 0.17; 95% confidence interval 0.14-0.21). Median survival for all patients was 7 months. Factors associated with improved survival were being female, black race, having limited-stage disease, receiving any treatment, and having a lower comorbidity score. Quantile regression demonstrated that chemotherapy provided a 6.5-month improvement in median survival (95% confidence interval 6.3-6.6; p<0.001).
conclusionsStatistically significant differences in the receipt of chemotherapy exist among elderly patients with SCLC. Chemotherapy is associated with a greater than 6-month improvement in median survival among elderly patients with SCLC, even in patients over the age of 80 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.